Currently, NB patients are stratified into low-, intermediate-, or high-risk categories based on risk assessment of well-defined prognostic factors including the age at diagnosis [3], International Neuroblastoma Staging System (INSS) stage [4], tumor histopathology [5], MYCN amplification status [6,7] and tumor DNA ploidy [8]. The gene discussed is MYCN; the disease is neoplasm.